Effective corrosion management demands a holistic approach: Experts

From material selection to cooling tower management, every small decision affects long-term equipment reliability

Cosmo Plastech expands rigid packaging solutions for pharma industry with PET sheets

PET sheets are widely recognised for their superior clarity, strength, and barrier properties

Advances in genetic testing, fertility preservation, and ART are reshaping reproductive care across India: Dr. Umesh N Jindal, Director, Jindal IVF

Dr. Jindal reflects on bridging accessibility gaps between urban and rural regions, the ethical and emotional aspects of family building, and how initiatives like adoption facilitation centers align with his lifelong mission to help couples realize the dream of parenthood

FDA grants breakthrough status to Augurex’s SPINEstat test to advance early axSpA diagnosis

GSK signs $745 million licensing agreement with Empirico for novel respiratory siRNA therapy

The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio

India’s healthcare and pharma sectors recorded a total of 72 transactions valued at US$ 3.5 billion in Q3 2025: Grant Thornton Bharat

The quarter included three IPOs worth US$ 428 million and one Qualified Institutional Placement (QIP) worth US$ 88 million

FDA approves Bayer’s Lynkuet as first hormone-free therapy for menopausal hot flashes

This approval marks a significant milestone in women’s health, introducing Bayer’s first hormone-free treatment for menopause-related symptoms

Novartis to acquire Avidity Biosciences for $12 billion

The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company

Sanofi’s Efdoralprin Alfa shows superiority in phase 2 Alpha-1 antitrypsin deficiency study

Efdoralprin Alfa was well tolerated, with a safety profile comparable to plasma-derived therapy

Takeda and Innovent Biologics forge global partnership to advance oncology medicines for solid tumors

Takeda will make an upfront payment of $1.2 billion, which includes a $100 million equity investment in Innovent